Drug prices and trends for PHENAZOPYRIDINE

Subscribe to access the full database, or Get Started Free
Drug Name	NDC	Price/Unit ($)	Unit	Date
PHENAZOPYRIDINE 100 MG TAB	75826-0114-10	0.17264	EACH	2025-11-19
PHENAZOPYRIDINE 200 MG TAB	42192-0802-01	0.18525	EACH	2025-11-19
PHENAZOPYRIDINE 100 MG TAB	69367-0611-01	0.17264	EACH	2025-11-19
PHENAZOPYRIDINE 200 MG TAB	65162-0682-10	0.18525	EACH	2025-11-19
PHENAZOPYRIDINE 100 MG TAB	42192-0801-01	0.17264	EACH	2025-11-19
PHENAZOPYRIDINE HCL 95 MG TAB	00536-1411-07	0.12642	EACH	2025-11-19
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: July 27, 2025

Introduction

Phenazopyridine, a urinary analgesic used to alleviate pain, burning, and discomfort associated with urinary tract infections (UTIs), remains a critical component of symptomatic management in urology. Its unique mechanism as a dye-based agent providing localized analgesia to the urinary tract makes it a valuable prescription drug, despite its over-the-counter availability in some countries. This analysis explores current market dynamics, key drivers, competitive landscape, and price projections for phenazopyridine over the upcoming five years.

Market Overview

Current Market Size and Trends

Global sales of phenazopyridine primarily originate from mature markets like the United States, Europe, and parts of Asia. The U.S. market is the largest, driven by high UTI prevalence, particularly among women, with estimates suggesting over 50% of women experience a UTI at least once. Phenazopyridine is frequently prescribed alongside antibiotics, contributing to its steady demand.

According to IQVIA data, the global urinary analgesics market, which includes phenazopyridine, was valued at approximately $1.2 billion in 2022.[1] Phenazopyridine accounts for roughly 35% of this sector, translating to market revenues close to $420 million globally. The U.S. dominates, capturing around 60–65% of sales, owing to high prescription rates and over-the-counter sales.

Market Dynamics

Rising UTI Incidence: An increase in urinary tract infections—linked to antibiotic resistance, aging populations, and lifestyle factors—propels demand.
Healthcare Modernization: Growing awareness and better diagnosis stimulate prescription volumes.
Regulatory Environment: USFDA-approved formulations and OTC availability in certain regions influence market access.
Safety Considerations: Phenazopyridine’s black box warning for potential nephrotoxicity and hemolytic anemia influences prescribing practices and OTC availability, impacting market size.
Biosimilars and Generics: Multiple generic formulations are available, exerting pricing pressure but expanding accessibility.

Key Drivers and Challenges

Drivers

High UTI Prevalence: As a common secondary therapy, phenazopyridine’s demand correlates strongly with UTI treatment volumes.
Elderly Population Growth: Aging demographics are more susceptible to UTIs, forecasted to increase phenazopyridine utilization.
Combination Therapy Patterns: Its use as adjunct therapy sustains steady sales.

Challenges

Safety Profile: The risk profile prompts cautious prescribing and ongoing safety assessments, occasionally limiting use.
Regulatory Restrictions: Differing OTC regulations across markets influence distribution channels and sales.
Antimicrobial Stewardship Strategies: Emphasis on reducing symptomatic treatments without antibiotics could impact demand.

Competitive Landscape

The phenazopyridine market is characterized by:

Patent and Formulation Status: Mostly generic formulations. The drug’s patent has long expired, intensifying price competition.
Leading Manufacturers: Major players include Pfizer, Mylan, Teva Pharmaceuticals, and Sandoz, producing generic phenazopyridine tablets.
Market Entry Barriers: Low due to generic availability, though regulatory hurdles in different jurisdictions can pose limitations.
Innovation Potential: Limited scope given the drug’s age, but formulation improvements or combination products present future opportunities.

Price Trends and Projections

Historical Pricing Data

Currently, the price of phenazopyridine varies by formulation, dosage, and market:

United States: Generic phenazopyridine (200 mg, 50 tablets) averages $10–$20, depending on pharmacy and insurance coverage.[2]
Europe and Asia: Prices are generally lower, ranging from $5–$15 per package**, reflecting different regulatory and supply dynamics.

Historical data indicates a decline in retail prices of approximately 2–3% annually over the past decade, primarily due to increasing generic competition and manufacturing efficiencies.

Projected Price Trends (2023–2028)

Short-term (2023–2025): Prices are expected to stabilize or slightly decline amid intense generic competition. Price declines of 1–2% annually are probable, driven by market saturation.
Mid-term (2025–2028): Marginal reductions or stabilization are expected as market saturation persists. However, due to inflation, raw material costs, and regulatory costs, prices may remain relatively stable with minor fluctuations.

Price Premiums and Market Segmentation:

Branded formulations—if introduced—might command a 10–15% premium but face stiff competition from generics.
Treatment settings: OTC formulations tend to be more competitively priced, impacting prescription prices.
Regional Differences: In emerging markets, prices may remain lower due to manufacturing costs and regulatory environments.

Influencing Factors

Regulatory Decisions: Stricter safety guidelines or reformulations could influence manufacturing costs, impacting prices.
Global Supply Chain Dynamics: Disruptions may cause transient price fluctuations.
Pricing Policies: Payer negotiations and formulary placements will influence retail prices.
Emerging Alternatives: Development of new formulations or combination therapies could influence phenazopyridine’s market positioning and pricing.

Regulatory and Market Access Outlook

Regulatory agencies are emphasizing safety, which influences market access:

The FDA mandates black box warnings concerning potential adverse effects.
Variability exists in OTC availability; some jurisdictions restrict sale to prescription only, impacting price and volume.
Approval of new formulations or routes—like sustained-release variants—could alter market dynamics and pricing strategies.

Conclusion and Strategic Insights

The phenazopyridine market remains stable, with modest downward price pressures stemming from generic competition and market saturation. However, regulatory safety concerns, changing treatment guidelines, and demographic shifts will shape its trajectories. Businesses should focus on optimizing supply chains, advocating for regulatory clarity, and pursuing formulations that enhance safety profiles to sustain profitability.

Key Takeaways

The global phenazopyridine market was valued at approximately $420 million in 2022, dominated by North American sales.
Market growth is primarily driven by increasing UTI prevalence, aging populations, and consistent use as an adjunct to antibiotics.
Price projections suggest slight annual declines (1–2%) over the next five years, attributable to generic competition.
Regulatory safety considerations may influence both market access and pricing, especially in regions tightening safety requirements.
Companies should monitor emerging safety profile data, regulatory changes, and regional market access policies to devise responsive pricing and expansion strategies.

FAQs

1. What are the main factors influencing phenazopyridine pricing?
Market competition, regulatory safety warnings, regional price differences, supply chain dynamics, and formulation innovations largely influence phenazopyridine pricing.

2. How might regulatory safety concerns impact future market share?
Enhanced safety warnings and potential restrictions could limit prescribing and OTC sales, reducing market size but possibly increasing demand for safer formulations.

3. Are there significant opportunities for innovation in phenazopyridine formulations?
Limited, given the drug’s age, but sustained-release formulations or combination therapies that improve safety and adherence could provide a competitive edge.

4. How does the regional variation affect phenazopyridine’s market?
Markets with lax regulations or high disease prevalence may see higher utilization and lower prices, while stricter regions may restrict OTC sales, impacting revenue.

5. What is the outlook for biosimilar or generic competition?
Considering the patent expiry and multiple manufacturers, generic phenazopyridine will continue to dominate, exerting continuous downward pressure on prices over the next decade.

Sources
[1] IQVIA, Global Urinary Analgesics Market Data, 2022.
[2] GoodRx, Pricing Data for Phenazopyridine (2023).

Drug Price Trends for PHENAZOPYRIDINE

Average Pharmacy Cost for PHENAZOPYRIDINE

Market Analysis and Price Projections for Phenazopyridine